For example, the deregulated mTORC1 signaling in Eμ-Myc lymphomagenesis can be used by treatment with the mTORC inhibitor everolimus, even at the pre-malignant stage, to delay lymphoma onset [55]. This evidence concerns the gene MYC and lymphoma.